UnitedHealth Beats Profit Estimates, Raises 2026 EPS Guidance to $19.50-$20.00

businesscompany-earnings 7 posts · 7 accounts

UnitedHealth Group reported second-quarter adjusted earnings per share of $6.38, surpassing analyst estimates of $4.85, and raised its full-year 2026 adjusted EPS guidance to a range of $19.50-$20.00. The company posted revenue of $112.0B and a medical care ratio of 86.7%, both beating consensus forecasts.

The top line remained flat year-over-year, driven by $86.0B in UnitedHealthcare revenue and a 2% decline to $65.7B for Optum. Management highlighted operational improvements, with Optum operating income jumping 29%. The company also set operating cash flow guidance at roughly $24.0B and increased its share repurchase target to at least $5.0B.

From the sources (7 posts)

@wallstengine

UNITEDHEALTH GROUP $UNH Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $112.0B (Est. $110.8B) 🟢; flat YoY 🔹 Adj. EPS: $6.38 (Est. $4.85) 🟢; +56% YoY 🔹 MCR: 86.7% (Est. 88.6%) 🟢; -270 bps YoY 🔹 UnitedHealthcare OI: $3.9B; +86% YoY (Est. +40.7% YoY) 🟢

@stocksavvyshay

$UNH Q2 EARNINGS • Revenue $112.0B vs Est. $110.8B • EPS $6.38 vs Est. $4.85 • Medical Care Ratio 86.7% vs. Est. 88.6% FY26 Guidance • EPS $19.75 vs Est. $18.32 • Medical Care Ratio: 88.1% vs. Est. 88.8%

@stockmktnewz

UNITEDHEALTH $UNH JUST REPORTED EARNINGS EPS $6.04 beating expectations of $3.74🟢 Revenue of $112B beating expectations of $110.7B🟢

@cnbc

UnitedHealth blows past estimates, hikes earnings outlook as it reins in costs

@financialjuice

$UNH UnitedHealth Q2 Earnings: Adj. EPS $6.38, est. $4.89 EPS $6.04 vs. $3.74 y/y Rev. $112.03B, est. $110.67B UnitedHealthcare segment rev. $86.02B, est. $84.91B Optum rev. $65.7B, est. $65.1B Medical care ratio 86.7%, est. 88.4% Oper cost

@firstsquawk

United Health Q2 2026 Earnings - Adj EPS $6.04 (est $3.74) - FY Adj EPS $19.50 To $20, Saw Above $18.25 - Rev $112.03B (est $110.67B) - Optum Revenue $65.7B (est $65.1B) - Healthcare Segment Rev. $86.02B (est $84.91B)

@wsj

UnitedHealth posted strong results and raised its full-year earnings projection, moves likely to bolster Wall Street’s belief in the company’s financial turnaround

Market impact

52 medium

UNH HUM ELV CI CVS XLV

Why it matters: UNH's large EPS beat and a medical-care-ratio well below expectations (86.7% vs ~88.6%) plus a raised FY26 guide confirms a cost-control turnaround and eases the sector-wide medical-cost-trend fear, reading through to managed-care peers and XLV.

At publish time: Headline states a clear beat ($6.38 vs $4.85) and a raised 2026 EPS guide to $19.50-$20.00, with the summary's 86.7% MCR beat being the sector-relevant hook — tradable at publish.

model confidence: medium

What happened next

1–2 weeks later

played out moved up

UNH held/extended gains post-beat (~$425 on 7/17 to ~$436 by 7/21); multiple analyst PT upgrades on low medical-cost ratio and raised FY26 guide.

based on follow-up coverage

Follow-up coverage

No follow-up coverage matched this story.

Uber Launches $14.8 Billion Takeover Bid for Delivery Hero Iranian Attack in Jordan Kills 2 U.S. Service Members, Leaves 1 Missing